Alpine Immune Sciences Inc Stock News

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflamma

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Alpine Immune Sciences Inc (ALPN) shares closed this week 22.5% lower than it did at the end of last week. The stock is currently down 22.5% year-to-date, down 20.2% over the past 12 months, and up 19.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $14.17 and as low as $10.57 this week.Shares closed 29.1% below its 52-week high and 36.3% above its 52-week low.Trading volume this week was 16.1% lower than the 10-day average and 44.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8544.2% The company's stock price performance over the past 12 months lags the peer average by 171.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflamma

Alpine Immune Sciences, Inc. (NASDAQ:ALPN)s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.44 and traded as high as $14.20. Alpine Immune Sciences shares last traded at $13.95, with a volume of 557,035 shares. Separately, Zacks Investment Research raised shares of Alpine []

(RTTNews) - Alpine Immune Sciences, Inc. (ALPN) and Horizon Therapeutics plc (HZNP) announced a license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine''s discovery platform. The agreement includes licensing of a lead, potential first-in-class preclinical candidate,

State Street Corp acquired a new stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 173,119 shares of the biotechnology companys stock, valued at approximately $1,558,000. State Street Corp owned approximately 0.72% of Alpine Immune Sciences []

Alpine Immune Sciences (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a strong sell rating to a hold rating in a research report issued on Monday, Zacks.com reports. According to Zacks, Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of []

Northern Trust Corp boosted its holdings in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) by 470.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 113,579 shares of the biotechnology companys stock after acquiring an additional 93,666 shares during the quarter. []

Equities research analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will announce earnings of ($0.49) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Alpine Immune Sciences earnings, with estimates ranging from ($0.58) to ($0.44). Alpine Immune Sciences reported earnings per share of ($0.27) in the same quarter []

Activists file with the SEC on Bird Global, Janus Henderson Group, Alpine Immune Sciences, and Hain Celestial Group